Angiogenesis is the growth of new blood vessels from a pre-existing vasculature. The deregulation of this physiological process is involved in several pathologies including cancer and inflammatory diseases (atherosclerosis, rheumatoid arthritis or age-related macular degeneration). Consequently, the research for drugs able to disrupt abnormal angiogenesis constitutes an essential research field [1] .
Angiogenic sprouting of blood vessels depends on the balance between pro-and antiangiogenic molecules. Among them, the vascular endothelial growth factor (VEGF A) is the major contributor to tumor angiogenesis [2] . The predominant isoform of VEGF A in humans is named VEGF 165 , according to its length in amino acids. VEGF 165 pro-angiogenic activity is mediated through binding to two high-affinity tyrosine kinase receptors: VEGF receptor 1 (VEGF-R1, Flt-1) and VEGF receptor 2 (VEGF-R2, KDR), located predominantly at the surface of endothelial cells but also on several tumour cell lines [3] . Neuropilin-1 (NP-1), a non-tyrosine kinase receptor of VEGF 165 , acts as a co-receptor, enhancing the activity of VEGF-R2 [4] . The specific role of VEGF-R1 is still a matter of debate. It acts as a negative regulator of angiogenesis during development but an increasing number of papers tend to demonstrate its specific implication as a promoter of angiogenesis under pathological conditions [5] .
Considering the central role displayed by the system VEGF 165 /VEGF-R1 in diseaseassociated angiogenesis, it constitutes an attractive target for the development of antiangiogenic therapies. Among the several strategies developed to disrupt this interaction, a promising approach is constituted by antagonist molecules, with a high affinity for the extracellular domain of the receptor, able to prevent VEGF 165 binding on VEGF-R1 [6] .
The affinity of these molecules is commonly evaluated thanks to a radioactive competition test: the tested compound and radiolabeled [ 125 I]VEGF 165 are incubated with cells expressing VEGF receptors [7] , membranes from endothelial cells [8] or directly with 2 HAL author manuscript inserm-00168674, version 1 recombinant receptors coated on microplates [9] , and the remaining activity after washes is measured. Unfortunately, the increasing logistical and regulatory difficulties associated with the use of radioactive isotopes threaten to limit the usefulness of this method. Consequently, the discovery of antagonists is limited by the unavailability of a safe and low-cost highthroughput screening test, and therefore, few antagonists have been reported to date [6] . To help in the discovery of potential new antiangiogenic therapeutics, we have developed a robust non-radioactive assay system for screening of VEGF receptors ligands. Our test is based on competition between compounds and biotinylated VEGF 165 (btVEGF 165 ), which is detected by chemiluminescence ( Fig. 1 ). This test is performed with the extra-cellular domain (ECD) of recombinant human VEGF-R1, allowing the discovery of receptor-specific molecules. Indeed, cell lines over-expressing one of the receptors proved to be not always a reliable system for testing ligand specificity due to the constitutive co-expression of other receptors, as attested by Perret et al who described for the first time a VEGF-R2 specific antagonist whose biological effect was in fact triggered by interaction with NP-1 [7, 10] .
In a first step, we determined the affinity of btVEGF 165 for VEGF-R1 ECD. The the one found by Barleon et al. [11] . Considering that performing the assay with recombinant receptors does not allow to reproduce the favourable effect of membrane microenvironment existing in cell based assays, it is not surprising to obtain a value superior to the K d previously described for VEGF 165 interaction with Cos cells transfected with VEGF-R1 (10-30 pM) [12] . In addition, our competition assay with unlabeled VEGF 165 (Fig. 2 B) demonstrates that 50% of biotinylated ligand binding (introduced at 131pM) was inhibited by 387 ± 60 pM of unlabeled VEGF 165 . This result proves that the btVEGF 165 exhibits roughly the same affinity for VEGF-R1 ECD as unlabeled VEGF 165 .
Another key point in developing a screening assay is the assessment of its robustness in the presence of dimethylsulfoxyde (DMSO). As a matter of fact, screening of chemical libraries is typically conducted in the presence of low concentrations of DMSO to avoid problems of solubility. We controlled that weak DMSO concentrations (0.63%, 1.25% and 2.5% v/v) had no significant effect on btVEGF 165 binding to VEGF-R1 ECD. The effect was more obvious at 5% and 10% DMSO, leading to respectively, 32% and 46% decrease of specific binding signals. Nevertheless, the reproducibility of the experiment performed on triplicate wells was not affected in all cases. Based on these data, a final concentration of 1% DMSO was chosen for development of the assay, allowing the screening of most of chemical compound libraries.
It follows then that this assay represents a strong asset in the search of small-molecule ligands of VEGF-R1. Thus, we verified that molecules exhibiting a weak affinity for the receptor could be readily identified using this screening test. Therefore, we evaluated the affinity of peptides previously described in the literature as ligands of VEGF receptors (Fig. 2   B ). Peptides were synthesized by solid phase peptide synthesis on an Applied Biosystems 433A synthesizer (Applied Biosystems, USA) using Fmoc chemistry. They were purified to 5 HAL author manuscript inserm-00168674, version 1 at least 95% purity by semi-preparative reverse phase HPLC and their identity was confirmed by electron spray MS (LCQ Advantage, Thermo Electron Corporation, USA).
QK (Ac-KLTWQELYQLKYKGI-NH 2 ) is a VEGF mimicking peptide [8] , exhibiting an agonist activity for VEGF receptors. Its affinity was determined by competition with [ 125 I]VEGF 165 for the binding sites of VEGF on cell membranes isolated from bovine aorta endothelial cells which express VEGF-R1, VEGF-R2 and NP-1 receptors. This assay leads to an IC 50 estimated in the nanomolar range. Tested on our screening assay, its IC 50 for VEGF-R1 was measured at 32 µM. Based on this result, it can be hypothesized that the high affinity of QK for endothelial cells may be triggered essentially by its binding to VEGF-R2/NP-1.
SP5.2 (NGYEIEWYSWVTHGMY-NH 2 ) has been described as a VEGF-R1 specific antagonist peptide, identified by phage display library screening [13] . To evaluate its affinity for the receptor, El-Mousawi et al. synthesized a fluorescein-labeled SP5.2 peptide and measured the fluorescence signal due to peptide binding to immobilized VEGF-R1/Fc chimera (1 µg/well) in a saturation assay. Based on this experiment, SP5.2 binding was dosedependent, with a half-maximum value at 40 µM. This in vitro value on purified receptor is in the same order of magnitude than the IC 50 obtained for SP5.2 in our chemiluminescent competition assay, measured at 28 ± 7 µM.
As a negative control, we chose the peptide A7R (ATWLPPR) initially described as a VEGF-R2 specific antagonist and which recently proved to be a NP-1 specific ligand [7, 10, 14] . As expected, no displacement of btVEGF 165 was observed in the range of concentrations tested (3-100 µM).
Finally, we verified if the screening assay could allow the identification of larger inhibitors of VEGF 165 . Thus, we tested a monoclonal antibody raised again VEGFR-1 ECD (anti-VEGFR-1, clone FLT-19, Sigma-Aldrich). This antibody proved to be able to displace btVEGF 165 binding to VEGFR-1 with an IC 50 of 2.81 ± 1.59 nM (supplementary data).
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In summary, the current study describes a method for identifying ligands of VEGF receptor 1 based on chemiluminescent detection of biotinylated VEGF 165 binding to the recombinant receptor. This assay has been developed on an easy to handle 96-well format.
Considering the small amounts of proteins used and the suppression of radioactivity issues, this assay represents an interesting progress for the evaluation of new VEGF-R1 ligands and should allow the screening of chemical libraries, even by academic institutions.
